Menaka Sarav, MD
Nephrology · New Haven, CTNPI 1548425168
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.4% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $558 and has fallen 81.6% since, to $103 in 2024.
Across 62 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$429
- Amgen$372
- AstraZeneca$342
- GSK$178
- ANI Pharmaceuticals, Inc.$99
- Akebia Therapeutics Inc$73
- plus $373 from 12 others
Across 1 payment — averaging $16,058 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$16K
What the payments were for
- Food & beverage$1,79996%
- Education$684%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 11 | $429 |
| Amgen(2 entities) | 9 | $372 |
| AstraZeneca(2 entities) | 12 | $342 |
| GSK | 4 | $178 |
| ANI Pharmaceuticals, Inc. | 4 | $99 |
| Akebia Therapeutics Inc | 3 | $73 |
| OPKO Pharmaceuticals, LLC | 3 | $68 |
| Aurinia Pharma U.S., Inc. | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 3 | $47 |
| Calliditas Therapeutics US Inc. | 2 | $40 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Shire North American Group Inc | 1 | $24 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| AMAG Pharmaceuticals, Inc. | 1 | $20 |
| Medtronic | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- (815) Thiola$127
- LOKELMA$127
- BENLYSTA$124
- KRYSTEXXA$113
How this compares
$1,868 in reported general payments places this provider in the 70th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LokelmaSodium Zirconium Cyclosilicate | 31 | $31,936 |
| VeltassaPatiromer Calcium Sorbitex | 17 | $19,899 |
| KerendiaFinerenone | 15 | $16,432 |
| FarxigaDapagliflozin Propanediol | 14 | $14,133 |
| Sevelamer Carbonate | 19 | $5,068 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,057 |
| Bumetanide | 13 | $830 |
| Amlodipine Besylate | 123 | $764 |
| Losartan Potassium | 83 | $656 |
| Nifedipine ErNifedipine | 12 | $633 |
| Valsartan | 25 | $525 |
| Lisinopril | 59 | $498 |
| Spironolactone | 53 | $419 |
| Torsemide | 38 | $412 |
| Potassium Chloride | 13 | $409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLokelma, Farxiga | $342 | $46,06845 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $99 | $52525 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 144 nephrology providers in Connecticut.
Other nephrology in New Haven
- Robert AlpernNew Haven$4.9M
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- Ladan GolestanehNew Haven$54K
- Aldo PeixotoNew Haven$17K
- Ali Abu-AlfaNew Haven$16K
- Lloyd CantleyNew Haven$14K
- Sue ChangNew Haven$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.